Pakistan Journal of Pharmaceutical Sciences. 2012; 25 (2): 349-352
Dans Anglais
| IMEMR
| ID: emr-128888
ABSTRACT
Hepatitis B virus [HBV] affects more than 350 million people worldwide and is a leading cause of morbidity and mortality in developing countries like Pakistan. Lamivudine has potential to inhibit hepatitis B virus [HBV] replication but long term lamivudine treatment results in mutations in YMDD region of HBV, making this therapy ineffective. In this study, we have optimized a polymerase chain reaction-restriction fragment length polymorphism [PCR-RFLP] based protocol to detect two mutations in HBV DNA polymerase gene [at codon 528 and 552] in chronic hepatitis patients, without any prior lamivudine treatment. HBV genome was extracted and tested by PCR-RFLP for detection of mutations in polymerase gene. Variations in HBV genome were not detected in enrolled patients confirming that lamivudine can be used to treat chronic Hepatitis B in these patients. Several studies have reported the natural occurrence of mutation in YMDD motif of polymerase gene in chronic hepatitis B patients, not treated with lamivudine, but these mutants were not detected in Pakistani lamivudine-untreated chronic hepatitis B patients
Recherche sur Google
Indice:
Méditerranée orientale
Sujet Principal:
Polymorphisme de restriction
/
Produits du gène pol
/
Virus de l'hépatite B
/
Réaction de polymérisation en chaîne
/
Lamivudine
/
Mutation
Limites du sujet:
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Pak. J. Pharm. Sci.
Année:
2012
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS